BPC July 7 updates: Clinical hold placed on JUNO -JCAR015. KITE still on track for Phase 2 ZUMA-1 data + BLA filing 2H 2016. TXMD NDA filing + updates for ALNY CTIX MCRB NVLS PLX

Jul 08, 2016 No Comments

Updates to the Company Pipeline Database for July 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ALNY 61.52 ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017 CTIX 1.28 Prurisol Placque psoriasis Phase 2b Phase 2b trial to be […]

Read more

BPC July 5 updates: INSY FDA Approval. CANF fails to meet Phase 2 primary endpoint. CEMP PDUFA date set for late December + updates for IPCI PRTA RGNX

Jul 06, 2016 No Comments

Updates to the Company Pipeline Database for July 6, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary CANF 2.11 CF101 Glaucoma Phase 2 Phase 2 failed to meet endpoint – July 2016 CEMP 16.93 Solithera – oral Community-acquired bacterial pneumonia (CABP) PDUFA PDUFA December 27 2016 CEMP 16.93 Solithera – […]

Read more

BPC July 1 updates: FDA determines that PTIE DRRX Advisory Committee Meeting is NOT required + ALNY XBIT AEZS updates

Jul 02, 2016 No Comments

Updates to the Company Pipeline Database for July 1, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AEZS 3.61 Zoptrex Castration and taxane resistant prostate cancer Phase 3 Phase 3 trial to be completed 3Q 2016 ALNY 61.44 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 […]

Read more

BPC updates June 30: ARRY Binimetinib NDA filing. AMPE fails to meet Phase 3 endpoints. CYNA Phase 3 data now due end of 3Q + updates for ARQL CYTK ITCI NDRM

Jul 01, 2016 No Comments

Updates to the Company Pipeline Database for June 30, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AMPE 1.29 Ampion Osteoarthritis of the Knee Phase 3 STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint – June 2016 ARQL 1.90 […]

Read more

BPC updates June 29: Poles apart – TSRO soars over 100% while GALE crashes over 80% on data releases. LPCN issued CRL + updates for ATNM BPMX CARA GBT

Jun 29, 2016 No Comments

Updates to the Company Pipeline Database for June 29, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ATNM 1.77 Iomab-B Hematopoietic Stem Cells Transplantation Phase 2 Phase 3 to be initiated June 2016 BPMX 0.66 BPX-01 Acne Phase 2a Phase 2a top-line data released June 2016. Phase 2b to be […]

Read more

BPC June 28 updates: ANTH CYAD ESPR fall on disappointing updates. EGLT Advisory Committee Meeting August 4 + updates for ACRX BLRX CHRS EARS INFI ITCI KTOV MRNS NDRM RARE XNCR XOMA

Jun 29, 2016 No Comments

Updates to the Company Pipeline Database for June 28, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ACRX 2.50 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 top-line data due 3Q 2016, with potential NDA filing by end of 2016 ANTH 3.07 Blisibimod Lupus Phase 3 Missed primary endpoints in […]

Read more

BPC June 27 updates: MRNS data due TODAY. RGLS tumbles on news of clinical hold. AAAP PDUFA date set for December 26 + updates for PBYI MDCO TBRA

Jun 27, 2016 No Comments

Updates to the Company Pipeline Database for June 27, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary AAAP 27.77 Lutathera Inoperable progressive midgut NETs PDUFA priority review PDUFA date under priority review December 28, 2016 MDCO 33.28 CARBAVANCE Complicated urinary tract infections (cUTI) NDA Filing Phase 3 data met endpoints […]

Read more

BPC June 23 updates: INNL Phase 3 data due 3Q or early 4Q. ARGL Phase 2 prelim data due June 30 + CAPR CERU RETA

Jun 24, 2016 No Comments

Updates to the Company Pipeline Database for June 23, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ARQL 1.92 ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 2 Phase 2 preliminary data due June 30, 2016 at ESMO 18th World Congress on Gastrointestinal Cancer CAPR 4.38 CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) […]

Read more

BPC June 22 updates: ARDX Phase 2b ESRD data timeline extended to 1Q 2017. ADMS FDA filing due 2016 + updates for INCY AGEN EPZM

Jun 23, 2016 No Comments

Updates to the Company Pipeline Database for June 22, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Summary ADMS 16.39 ADS-5102 – EASE LID trial Levodopa-Induced Dyskinesia NDA filing Phase 3 data released December 2015. NDA filing due 2016 AGEN 4.05 INCAGN1876 Solid tumors – cancer Phase 1/2 Phase 1/2 trial […]

Read more